锂空气电池固体电解质Li_(1+x)Al_xTi_(2-x)(PO_4)_3的制备研究

以Li_2CO_3、Al_2O_3、TiO_2、NH_4H_2PO_4为原料,采用固相烧结法制备锂空气电池固体电解质Li_(1+x)Al_xTi_(2-x)(PO_4)_3(LATP),研究了不同x值、不同烧结温度对电解质性能的影响。通过X射线衍射仪(XRD)、扫描电镜(SEM)和电化学阻抗谱(EIS)对所制备电解质的结构与性能进行表征。结果表明在x值等于0.2时得到纯相的LATP,最佳烧结工艺是350℃保温2 h,600℃保温2 h,1 000℃保温8 h,室温下的电导率为4.89×10~(-5)S/cm。     

Anti-AIDS agents. 33. Synthesis and anti-HIV activity of mono-methyl substituted 3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogues

Four isomeric methyl substituted DCK analogues (2-5) were asymmetrically synthesized from different starting materials. 3-Methyl, 4-methyl, and 5-methyl-3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (2-4) all were extremely potent against HIV-1 replication in H9 lymphocyte cells with EC50 and therapeutic index values of < 4.23 x 10(-7) microM and > 3.72 x 10(8), respectively, which are much better than those of DCK and AZT in this assay.     

Enzymatic synthesis of N-linked oligosaccharides terminating in multiple sialyl-Lewis(x) and GalNAc-Lewis(x) determinants: clustered glycosides for studying selectin interactions

Galactosyltransferase, sialyltransferase, and fucosyltransferase were used to create a panel of complex oligosaccharides that possess multiple terminal sialyl-Le(x) (NeuAc alpha 2-3Gal[Fuc alpha 1-3] beta 1-4GlcNAc) and GalNAc-Le(x) (GalNAc[Fuc alpha 1-3]beta 1-4GlcNAc). The enzymatic synthesis of tyrosinamide biantennary, triantennary, and tetraantennary N-linked oligosaccharides bearing multiple terminal sialyl-Le(x) was accomplished on the 0.5 mumol scale and the purified products were characterized by electrospray MS and 1H NMR. Likewise, biantennary and triantennary tyrosinamide oligosaccharides bearing multiple terminal GalNAc-Le(x) determinants were synthesized and similarly characterized. The transfer kinetics of human milk alpha 3/4-fucosyltransferase were compared for biantennary oligosaccharide acceptor substrates possessing Gal beta 1-4GlcNAc, GalNAc beta 1-4GlcNAc, and NeuAc alpha 2-3Gal beta 1-4GlcNAc which established NeuAc alpha 2-3Gal beta 1-4GlcNAc as the most efficient acceptor substrate. The resulting complex oligosaccharides were chemically tethered through the tyrosinamide aglycone to the surface of liposomes containing phosphatidylthioethanol, resulting in the generation of glycoliposomes probe which will be useful to study relationships between binding affinity and the micro- and macro-clustering of selectin ligand.     

Red Emitting Phosphor (Y, Gd) Bx V1- x O4- x :Eu3 + with High Color Purity for Plasma Display Panels

(Y, Gd)BxV1- xO4-x :Eu3 phosphors were prepared by solid state reaction. The red emission color purity of (Y, Gd)Bx V1 - x O4-x :Eu3 phosphor is much better than that of the recent widely-used commercial red emitting phosphor (Y,Gd)BO3:Eu3 and its relative emission intensity is 84% of the commercial phosphor (Y, Gd)BO3 :Eu3 . It is expected that (Y, Gd) Bx V1 -x O4: Eu3 phosphor will be a promising candidate for PDP (plasma display panels) application.     

Binding and catalytic properties of Xenopus (6-4) photolyase

Xenopus (6-4) photolyase binds with high affinity to DNA bearing a (6-4) photoproduct and repairs it in a light-dependent reaction. To clarify its repair mechanism of (6-4) photolyase, we determined its binding and catalytic properties using synthetic DNA substrate which carries a photoproduct at a single location. The (6-4) photolyase binds to T[6-4]T in double-stranded DNA with high affinity (KD = 10(-9)) and to T[6-4]T in single-stranded DNA and T[Dewar]T in double- and single-stranded DNA although with slightly lower affinity (KD = approximately 2 x 10(-8)). Majority of the T[6-4]T-(6-4) photolyase complex dissociates very slowly (koff = 2.9 x 10(-5) s-1). Its absolute action spectrum without a second chromophore in the 350-600 nm region closely matches the absorption spectrum of the enzyme. The quantum yield (phi) of repair is approximately 0.11. The fully reduced form (E-FADH-) of (6-4) photolyase is catalytically active. Direct analysis of the photoreactivated product showed that (6-4) photolyase restores the original pyrimidines. These findings demonstrate that cis, syn-cyclobutane pyrimidine dimer photolyase and (6-4) photolyase are quite similar, but they are different with regard to the binding properties.     

Plasma coatings of (TiCrC)-(FeCr) composite powder alloys: Structure and properties

The coatings of the (TiCrC)-(FeCr) composite are deposited on steel and titanium alloy by plasma method. The composition, structure, and tribotechnical properties of these coatings are studied in comparison with traditional materials based on the Ni-Cr alloy. The effect of preliminary surface treatment methods, i.e., sandblasting treatment and electrospark alloying, on coating properties is examined. The fretting corrosion of coatings is investigated. It is established that coatings based on double titanium-chromium carbide have considerably greater wear resistance than that of Ni-Cr alloys at almost equal friction coefficients. It is established that electrospark alloying is competitive with traditional sandblasting treatment in environmental effect and coating-to-based adhesion. __________ Translated from Poroshkovaya Metallurgiya, Vol. 46, No. 3–4 (454), pp. 37–45, 2007.     

Synthesis,Luminescence and Magnetic Properties of YGa_(3-x)Cr_xB_4O_(12)

Ｓｙｎｔｈｅｓｉｓ，ＬｕｍｉｎｅｓｃｅｎｃｅａｎｄＭａｇｎｅｔｉｃＰｒｏｐｅｒｔｉｅｓｏｆＹＧａ３－ｘＣｒｘＢ４Ｏ１２ＹａｎｇＪｉａｎｍｅｉ（杨健美），ＳｕＱｉａｎｇ（苏锵）（ＬａｂｏｒａｔｏｒｙｏｆＲａｒｅＥａｒｔｈＣｈｅｍｉｓｔｒｙａｎｄＰｈｙ...     

Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione

The administration of the compound 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) to rats (10 mg/kg body wt) caused an elevation in the concentration of plasma tyrosine and gave products in urine that were identified as 4-hydroxyphenylpyruvate (HPPA) and 4-hydroxyphenyllactate (HPLA). This observed chemically induced tyrosinemia established that this compound perturbs tyrosine catabolism and suggested that the causal effect is the inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD). This was confirmed when rat liver HPPD was found to be markedly inhibited by NTBC when the enzyme and chemical were incubated, in vitro, for 3 min at 37 degrees C prior to the initiation of the enzyme reaction by the addition of substrate. At 100 nM NTBC, approximately 90% of the enzyme activity was lost and an IC50 was calculated at approximately 40 nM. The inhibition of HPPD by NTBC (50 nM) is time-dependent; the enzyme activity was reduced by > 50% within 30 sec. Progress curve data of loss of enzyme activity with time gave a rate constant for the inactivation of rat liver HPPD [k*, formation of an HPPD-inhibitor (EI) complex] by NTBC of 9.9 +/- 2.5 x 10(-5) sec-1 nM-1. It was established that NTBC is not irreversibly bound in the EI complex but slowly dissociates with a recovery of enzyme activity of 13.7 +/- 1.0% over a 7-hr period (t1/2, 25 degrees C estimated at 63 hours). In comparison, the compound 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione (CMBC), an analog of NTBC, gave a similar rate for the inactivation of HPPD (k*, 3.3 +/- 0.8 x 10(-5) sec-1 nM-1), whereas 45 +/- 8% of the enzyme activity was recovered over a 7-hr period (t1/2, 25 degrees C approximately 10 hr). These studies establish that NTBC and CMBC are potent, time-dependent (tight-binding) reversible inhibitors of HPPD. The inhibition is characterized by a rapid inactivation of the enzyme by the formation of an HPPD-inhibitor complex that dissociates with recovery of enzyme activity. In vivo, the inhibition of HPPD causes a tyrosinemia that abates with the recovery of enzyme activity. The understanding of the mechanism by which NTBC perturbs tyrosine catabolism has led to the clinical use of this chemical as the first effective pharmacological therapy for the hereditary disorder tyrosinemia I.     

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist

Structural modifications requiring novel synthetic chemistry were made to the morpholine acetal human neurokinin-1 (hNK-1) receptor antagonist 4, and this resulted in the discovery of 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-ox o-1 ,2,4-triazol-5-yl)methyl morpholine (17). This modified compound is a potent, long-acting hNK-1 receptor antagonist as evidenced by its ability to displace [125I]Substance P from hNK-1 receptors stably expressed in CHO cells (IC50 = 0.09 +/- 0.06 nM) and by the measurement of the rates of association (k1 = 2.8 +/- 1.1 x 10(8) M-1 min-1) and dissociation (k-1 = 0.0054 +/- 0.003 min-1) of 17 from hNK-1 expressed in Sf9 membranes which yields Kd = 19 +/- 12 pM and a t1/2 for receptor occupancy equal to 154 +/- 75 min. Inflammation in the guinea pig induced by a resiniferatoxin challenge (with NK-1 receptor activation mediating the subsequent increase in vascular permeability) is inhibited in a dose-dependent manner by the oral preadmininstration of 17 (IC50 (1 h) = 0.008 mg/kg; IC90 (24 h) = 1.8 mg/kg), indicating that this compound has good oral bioavailbility and peripheral duration of action. Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of 17 as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC50 (4 h) = 0.04 +/- 0.006 mg/kg; IC50 (24 h) = 0.33 +/- 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge. The activity of 17 at extended time points in these preclinical animal models sets it apart from earlier morpholine antagonists (such as 4), and the piperidine antagonists 2 and 3 and could prove to be an advantage in the treatment of chronic disorders related to the actions of Substance P. In part on the basis of these data, 17 has been identified as a potential clinical candidate for the treatment of peripheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.     

Structure and Luminescent Enhancement Effect of Na_5Eu(MoO_4)_4 by Doping(WO_4)~(2-)

The luminescent enhancement effect of Na_5Eu(MoO_4)_4 by doping(WO_4)~(2-) has been studied.When the value x in Na_5Eu(Mo_(1-x)W_xO_4)_4 is in 0相似文献   

Characterization of Vacuum Plasma Sprayed Reinforced Hydroxyapatite Coatings on Ti–6Al–4V alloy

Two reinforced hydroxyapatite (HA) coatings with an intermediate layer of zirconia were deposited on Ti–6Al–4V by vacuum plasma spray (VPS) technique. In first coating, HA was reinforced with 10 wt % Al₂O₃ whereas in second coating, HA was reinforced with 10 wt % ZrO₂. The objective of this study was to investigate the microstructure, phase formation and mechanical properties like hardness and bond strength of as-sprayed coatings and the coatings after post coating heat treatment at 700 °C for 1 h. The characterization of the coatings was performed by using SEM/EDAX, XRD, porosity, crystallinity and roughness measurement. The coatings were also evaluated for mechanical properties like hardness and tensile bond strength. It was observed that after post coating heat treatment, crystallinity increased and porosity decreased which indicated recrystallization of amorphous phases of as-sprayed coatings. Heat treatment resulted into improvement in cross-sectional hardness, however sharp decrease in bond strength was observed.     

Microwave dielectric properties of Ba6-3xLa8+2x(Ti1-zZrz)18O54(x=2/3)ceramics

Zr substitution for Ti was investigated to modify the dielectric properties of Ba6-3xLa8+2xTi18O54(x=2/3) ceramics.A single-phase solid solution with tungstenbronze-like structure was formed in the range of 0     

Dielectric and Piezoelectric Properties of Ca1-x(Li,Ce)x/2Bi4Ti4O15 Ceramics

The influence of (Li, Ce)⁴⁺ on the properties (piezoelectric, dielectric ferroelectric properties) of bismuth layer (Ca_1-x(Li, Ce)_x/2Bi₄Ti₄O₁₅)(CLCBT) lead free piezoelectric ceramics used for high frequency and high temperature were investigated by means of conventional solid state method. The relationship between the additive amount of (Li, Ce)⁴⁺ and the properties of CLCBT ceramics were obtained. The influences of additive amount of (Li, Ce)⁴⁺ on the microstructure and material phase of CLCBT ceramies were studied by scanning electron microscope and X-ray diffraction. The mechanism for modifying the properties and microstructure of the CLCBT ceramics by (Li, Ce)⁴⁺ doping was investigated. Results showed that the lead free bismuth layer CLCBT ceramics having good comprehensive properties was obtained when the (Li, Ce)⁴⁺ additive amount was 0.075 mol, which the dielectric constant was 176.52, the dielectric loss was 0.00579, and the piezoelectric strain constant was 13 pC·N⁻¹. This materials was suitable to be used for high frequency and high temperature piezoelectric device, and so on. (Li, Ce)⁴⁺ doping could affect the properties and micro-structure of bismuth layer CLCBT ceramics by means of (Li, Ce)⁴⁺ substituting for Ca²⁺ in CLCBT, forming pyrochlore, densifying ceramics, stopping grain growing, forming Ca vacancy, and increasing specific resistance.     

Synthesis and Properties of Tb^3＋-Doped CaxSr1-xWO4

Tb^3 -doped CaxSr1-xWO4 was prepared by solid state reaction and characterized by powder X-ray diffractometry. According to X-ray diffraction, this material belongs to tetragonal system, which is consistent with space group 141/α. Lattice parameters in the systems CaxSr1-xWO4 were found to vary linearly with compositions. The emission and excitation spectra were measured. The miscibility, luminescence properties of Tb^3 -doped CaxSr1-xWO4 and energy transfer mechanism were discussed.     

Mechanical and histological evaluation of amorphous calcium phosphate and poorly crystallized hydroxyapatite coatings on titanium implants

The effect of amorphous calcium phosphate (Ca/P) and poorly crystallized (60% crystalline) hydroxyapatite (HA) coatings on bone fixation to "smooth" and "rough" (Ti-6A1-4V powder sprayed) titanium-6Al-4V (Ti) implants was investigated. Implants were evaluated histologically, mechanically, and by scanning electron microscopy (SEM) after 4 and 12 weeks of implantation in a rabbit transcortical femoral model. Histological evaluation of amorphous vs. poorly crystallized HA coatings showed significant differences in bone apposition (for rough-coated implants only) and coating resorption (for smooth- and rough-coated implants) that were increased within cortical compared to cancellous bone. The poorly crystallized HA coatings showed most degradation and least bone apposition. Mechanical evaluation, however, showed no significant differences in push-out shear strengths between the two types of coatings evaluated. Differences between 4 and 12 weeks were significant for coating resorption and push-out shear strength but not for bone apposition. Significant enhancement in interfacial shear strengths for bioceramic coated as compared to uncoated implants were seen for smooth-surfaced implants (3.5-5 times greater) but not for rough-surfaced implants at 4 and 12 weeks. Rough implants showed greater mean interfacial strengths than uncoated smooth implants at 4 and 12 weeks (seven times greater) and to coated smooth implants at 12 weeks only (two times greater). Mechanical failure of the bone/coating/implant interface consistently occurred within the bone, even in the case of the poorly crystallized HA coatings, which had almost completely resorbed on rough implants. These results suggest that once early osteointegration is achieved biodegradation of a bioactive coating should not be detrimental to the bone/coating/implant fixation.     

Potent inactivator of alpha-chymotrypsin: 2,2-dimethyl-3-(N-4-cyanobenzoyl)amino-5-phenyl pentanoic anhydride

We synthesized a novel potent alpha-chymotrypsin inactivator, 2,2-dimethyl-3-(N-4-cyanobenzoyl) amino-5-phenyl pentanoic anhydride, which fulfilled the criteria of a mechanism-based inactivator: first-order kinetics, irreversibility, saturation kinetics and substrate protection. The inactivation rate constant (kinact) and the enzyme-inhibitor dissociation constant (KI) were calculated to be 0.017s-1 and 0.071 microM, respectively (kinact/KI = 242,000 M-1s-1). These kinetic parameters indicate that this compound is one of the most powerful alpha-chymotrypsin inactivators ever reported. The average number of alpha-chymotrypsin turnovers per inactivation (partition ratio) was calculated to be 1, which indicates that it is a stoichiometrically ideal inactivator of alpha-chymotrypsin. We compared the IC50 values of this compound with those of several chymotrypsin-like serine proteinases (bovine alpha-chymotrypsin, recombinant human chymase and human neutrophil cathepsin G) and a metallo proteinase, rabbit angiotensin converting enzyme (ACE). Our compound, 2,2-dimethyl-3-(N-4-cyanobenzoyl) amino-5-phenyl pentanoic anhydride, inhibited bovine alpha-chymotrypsin potently (IC50 = 1.0 (+/- 0.2) x 10(-9) M) as well as other chymotrypsin-like serine proteinase; recombinant human chymase (IC50 = 7.0 (+/- 1.0) x 10(-8) M) and human neutrophil cathepsin G (IC50 = 1.8 (+/- 0.2) x 10(-7) M). However, rabbit ACE was not inhibited by this compound (IC50 > 1 x 10(-4) M).     

7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602)

A series of novel 7-[3-(1-piperidinyl)propoxy]chromenones was synthesized and tested as potential antipsychotics in several in vitro and in vivo assays. The compounds possessed good affinity for D2 receptors, together with a greater affinity for 5-HT2 receptors, a profile which has been proposed as a model for atypical antipsychotics. Several agents also displayed a high potency in the climbing mice assay on oral administration, suggesting a potent antipsychotic effect as compared to reference standards. Compound 23 was selected for further pharmacological evaluation. Induction of catalepsy and inhibition of stereotypies weaker than standards, along with a lower increase in serum prolactin levels, were indicative of a potential atypical profile for this compound. From these results, 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl )chromen- 4-one (23, abaperidone) has been proposed for clinical evaluation in humans as a potential atypical antipsychotic.     

Glycosyl-transferase catalyzed assemblage of sialyl-Lewis(x)-saccharopeptides

A series of glycohexopyranuronic acids are coupled to glucosamines to give 'disaccharides' which have the natural N-acetyl group of the glcNAc-moiety replaced by various sugar acids (-->saccharopeptides). These saccharopeptides are surprisingly good substrates for beta(1-4)galactosyl-transferase, alpha(2-3)sialyl-transferase, and fucosyl-transferase VI. The enzymes transfer successively galactose, sialic acid, and fucose from the corresponding donors onto these acceptor substrates--despite the far reaching alterations--regio- and stereospecifically in the expected manner to yield a new class of compounds, the sialyl-Lewis(x)-saccharopeptides.     

2,6-dialkylpiperazines. VIII (1)-N1-arylalkyl-N4-(2'-pyridyl)-2,6-dimethylpiperazines as adrenolytic and vasodilator agents

A series of cis and trans N1-arylalkyl-N4-(2'-pyridyl)-2'6-dimethylpiperazines were synthetized and tested as adrenolytic and vasodilator agents. The N1-substitution with the 3,4-dimethoxyphenethyl group seems the most promising with regard to pharmacological activity, which was found to reside mainly in the trans isomer (3-II b). The adrenolytic activity of (3-II b) is comparable with that of the related 2-methyl derivative (1-III), while it is higher than that of (IV) in which the piperazine nucleus is C-unsubstituted.